Michelle McMurry-Heath (BIO via YouTube)
October 11, 2022 04:25 AM EDTUpdated October 13, 06:43 AM
Bioregnum

Michelle Mc­Mur­ry-Heath washed over­board at BIO as in­dus­try group wres­tles over its fu­ture, hunts new CEO

In the end, the in­ter­nal ten­sions rip­ping at BIO had bare­ly sur­faced in fresh tur­moil then the stormy sur­face wa­ters were smoothed by CEO Michelle Mc­Mur­ry-Heath’s quick ex­it. Late Mon­day came word that she had re­signed from her top post, swap­ping it for an ad­vi­so­ry po­si­tion, and soon af­ter we learned that long­time biotech ex­ec Rachel King would be tak­ing her po­si­tion un­til they can find a full-time re­place­ment.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE
TRENDING NOW

As cash runs tight, blue­bird plunges af­ter pric­ing sick­le cell gene ther­a­py well above com­peti­tor and fail­ing to win ...

FDA ap­proves two gene ther­a­pies for sick­le cell dis­ease, in­clud­ing first that us­es CRISPR

Bris­tol My­ers’ lead deal ne­go­tia­tor to de­part af­ter ink­ing se­ries of multi­bil­lion-dol­lar ac­qui­si­tions

Three big win­ners from Ab­b­Vie's $8.7B Cerev­el deal: A drug­mak­er, a CEO and a SPAC

The End­points 100 sur­vey: Has biotech hit rock bot­tom?

sponsored

Ear­ly pre­dic­tion of out­comes in DL­B­CL clin­i­cal tri­als through MRD test­ing

A service from the Financial Times